Skip to main content
Premium Trial:

Request an Annual Quote

Isis Extends Antisense Drug Discovery Collaboration With Lilly

NEW YORK, May 6 (GenomeWeb News) - Isis Pharmaceuticals announced today that it is extending its collaboration with Eli Lilly to develop antisense-based cancer therapeutics.

 

Under the collaboration, which was originally forged in June 2002, the companies will continue to characterize and develop RNaseH, siRNA, and splicing modulating inhibitors as potential treatments, Isis said. In addition, the companies will explore the use of RNA-directed technology to find potential anticancer drug targets.

 

Financial terms of the extension were not disclosed.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.